BR0008637A - Uso de 15-deoxiespergualina para o tratamento de doenças inflamatórias hiper-reativas e doenças auto-imunes - Google Patents

Uso de 15-deoxiespergualina para o tratamento de doenças inflamatórias hiper-reativas e doenças auto-imunes

Info

Publication number
BR0008637A
BR0008637A BR0008637-1A BR0008637A BR0008637A BR 0008637 A BR0008637 A BR 0008637A BR 0008637 A BR0008637 A BR 0008637A BR 0008637 A BR0008637 A BR 0008637A
Authority
BR
Brazil
Prior art keywords
treatment
deoxiespergualin
diseases
inflammatory diseases
autoimmune diseases
Prior art date
Application number
BR0008637-1A
Other languages
English (en)
Inventor
Rainer Birck
Johannes Drexler
Osamu Hotta
Rainer Nowack
Fokku Johannes Van Der Woude
Original Assignee
Nippon Kayaku Kk
Euro Nippon Kayaku Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Kk, Euro Nippon Kayaku Gmbh filed Critical Nippon Kayaku Kk
Publication of BR0008637A publication Critical patent/BR0008637A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: "USO DE 15-DEOXIESPERGUALINA PARA O TRATAMENTO DE DOENçAS INFLAMATóRIAS HIPER-REATIVAS E DOENçAS AUTO-IMUNES". A invenção refere-se ao uso de deoxiespergualina (DSG) ou um análogo desta para a preparação de um medicamento para o tratamento de elou profilaxia contra doenças inflamatórias hiper-reativas e doenças auto-imunes, nas quais o tratamento é realizado em ciclos.
BR0008637-1A 1999-05-25 2000-04-14 Uso de 15-deoxiespergualina para o tratamento de doenças inflamatórias hiper-reativas e doenças auto-imunes BR0008637A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19923961A DE19923961A1 (de) 1999-05-25 1999-05-25 Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen
PCT/EP2000/003430 WO2000071103A2 (en) 1999-05-25 2000-04-14 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases

Publications (1)

Publication Number Publication Date
BR0008637A true BR0008637A (pt) 2002-01-08

Family

ID=7909146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008637-1A BR0008637A (pt) 1999-05-25 2000-04-14 Uso de 15-deoxiespergualina para o tratamento de doenças inflamatórias hiper-reativas e doenças auto-imunes

Country Status (20)

Country Link
US (2) US7153887B1 (pt)
EP (1) EP1180026B1 (pt)
JP (2) JP4422349B2 (pt)
KR (1) KR100681626B1 (pt)
CN (1) CN1199636C (pt)
AR (1) AR024071A1 (pt)
AT (1) ATE228833T1 (pt)
AU (1) AU762018B2 (pt)
BR (1) BR0008637A (pt)
CA (1) CA2362582C (pt)
CZ (1) CZ299440B6 (pt)
DE (2) DE19923961A1 (pt)
ES (1) ES2188538T3 (pt)
HU (1) HU228843B1 (pt)
MX (1) MXPA01008587A (pt)
PL (1) PL352314A1 (pt)
RU (1) RU2255732C2 (pt)
TW (1) TWI283175B (pt)
WO (1) WO2000071103A2 (pt)
ZA (1) ZA200106596B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042019A1 (en) * 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
AR048210A1 (es) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
PT2012814E (pt) * 2006-04-12 2013-07-18 Genzyme Corp Métodos de tratamento de doenças auto-imunes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
FR2698628B1 (fr) * 1992-12-02 1995-02-17 Fournier Ind & Sante Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
US5250442A (en) * 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
FR2716452B1 (fr) * 1994-02-24 1996-05-10 Fournier Ind & Sante Analogues de la 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
ATE173921T1 (de) * 1994-03-22 1998-12-15 Nippon Kayaku Kk Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
FR2734263B1 (fr) * 1995-05-17 1997-06-20 Fournier Ind & Sante Analogues de la 15-deoxyspergualine, leur procede de preparation et leur utilisation en therapeutique
US5679651A (en) * 1995-06-05 1997-10-21 Richardson; Bruce C. Treatment for systemic lupus erythematosus
DE19711803A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung mit 15-Deoxyspergualin
DE19728436A1 (de) * 1997-07-03 1999-01-07 Niels Franke Niedrigdosierte 15-Desoxyspergualin-Präparate
TW536400B (en) * 1997-07-18 2003-06-11 Nippon Kayaku Kk Pharmaceutical composition for the treatment of immunodeficiency disease which cause by HIV infection

Also Published As

Publication number Publication date
RU2255732C2 (ru) 2005-07-10
CZ299440B6 (cs) 2008-07-30
CN1199636C (zh) 2005-05-04
HUP0200354A2 (hu) 2002-05-29
KR20020010126A (ko) 2002-02-02
AU4550400A (en) 2000-12-12
JP2009263397A (ja) 2009-11-12
DE60000937D1 (de) 2003-01-16
ATE228833T1 (de) 2002-12-15
HU228843B1 (en) 2013-06-28
JP2003500351A (ja) 2003-01-07
CN1351490A (zh) 2002-05-29
DE60000937T2 (de) 2003-09-04
MXPA01008587A (es) 2003-06-24
WO2000071103A3 (en) 2001-06-21
DE19923961A1 (de) 2000-11-30
US20060293391A1 (en) 2006-12-28
EP1180026B1 (en) 2002-12-04
CA2362582C (en) 2008-10-07
CZ20014158A3 (cs) 2002-06-12
ES2188538T3 (es) 2003-07-01
EP1180026A2 (en) 2002-02-20
US7153887B1 (en) 2006-12-26
CA2362582A1 (en) 2000-11-30
AR024071A1 (es) 2002-09-04
KR100681626B1 (ko) 2007-02-09
HUP0200354A3 (en) 2003-03-28
PL352314A1 (en) 2003-08-11
US7776829B2 (en) 2010-08-17
JP4422349B2 (ja) 2010-02-24
ZA200106596B (en) 2002-08-12
TWI283175B (en) 2007-07-01
WO2000071103A2 (en) 2000-11-30
AU762018B2 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
BR0314763A (pt) Tratamento de infecções fúngicas
BRPI0112962B8 (pt) composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
BR0213358A (pt) Uso de flibanserina
CA2299361A1 (en) Use of consensus interferon in combination with il-1 receptor antagonist for treatment of patients afflicted with multiple sclerosis
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
BR9906438A (pt) Composição de reforço nutricional apropriada para o tratamento de úlceras de pressão
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
BR0108514A (pt) Uso de inibidores de il-18
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
PT902789E (pt) Derivados de androsteno
HUP0400548A2 (hu) Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
HUP0302333A2 (hu) Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0301506A2 (hu) Gyógyászati készítmények nedves hámfelületek fájdalmas, gyulladásos vagy fekélyes állapotai, így például nyálkahártyagyulladás, szájgyulladás és behcet-tünetcsoport kezelésére
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BR0008637A (pt) Uso de 15-deoxiespergualina para o tratamento de doenças inflamatórias hiper-reativas e doenças auto-imunes
BR9706938A (pt) Composto uso do mesmo formulação farmacêutica e processos para produzir o composto e para o tratamento ou a prevenção de sintomas ou efeitos de uma infecção virótica em um mamífero infectado incluindo um humano
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
HUP0401593A2 (hu) A PTX3 hosszú pentraxin alkalmazása gyógyhatású készítmény előállítására autoimmun betegségek megelőzésére és kezelésére

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 020120018252/RJ DE 05/03/2012, POR FALTA DE FUNDAMENTACAO LEGAL, UMA VEZ QUE O PEDIDO DE PATENTE FOI INDEFERIDO NA RPI 2131 DE 08/11/2011.

B25B Requested transfer of rights rejected

Owner name: NIPPON KAYAKU KABUSHIKI KAISHA (JP) , EURO NIPPON KAYAKU GMBH (DE)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 020120018252 DE 05/03/2012, CONFORME DISPOSTO NO ART. 59 DA LEI 9279 DE 14/05/1996, PELO FATO DO PEDIDO DE PATENTE TER SIDO INDEFERIDO NA RPI 2064 DE 27/07/2010 COM DECISAO MANTIDA EM GRAU DE RECURSO PUBLICADO NA RPI 2131 DE 08/11/2011.

Owner name: NIPPON KAYAKU KABUSHIKI KAISHA (JP) , EURO NIPPON

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]